{"id":1712,"date":"2023-06-25T17:32:51","date_gmt":"2023-06-25T17:32:51","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/ceftazidime\/"},"modified":"2023-06-25T19:40:22","modified_gmt":"2023-06-25T19:40:22","slug":"ceftazidime","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/ceftazidime\/","title":{"rendered":"Ceftazidime"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/kidneydiseaseclinic.net\/renaldrugs\/img\/Ceftazidime.JPG\"><\/p>\n<h1>Ceftazidime<\/h1>\n<h3>  CLINICAL USE<\/h3>\n<p>Antibacterial agent<\/p>\n<h3> DOSE IN NORMAL RENAL FUNCTION<\/h3>\n<p>0.5\u20132 g every 8\u201312 hours Severe infections: 3 g every 12 hours Pseudomonal lung infections in cystic  fibrosis: 100\u2013150 mg\/kg in 3 divided dosesSurgical prophylaxis: 1 g at induction<\/p>\n<h3>  PHARMACOKINETICS<\/h3>\n<li> Molecular weight &nbsp;  &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; :637.7<\/li>\n<li>  %Protein binding  &nbsp; &nbsp; &nbsp;  &nbsp;  &nbsp;  &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; :<\/li>\n<li> &lt;10 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; :<\/li>\n<li>  %Excreted unchanged in urine &nbsp; &nbsp; : 80\u201390<\/li>\n<li> Volume of distribution (L\/kg) &nbsp; &nbsp; &nbsp; :0.28\u20130.4<\/li>\n<li>half-life \u2013 normal\/ESRD (hrs)&nbsp; &nbsp; &nbsp; :2\/13\u201325<br \/>\n<h3>  DOSE IN RENAL IMPAIRMENT<\/h3>\n<h4>GFR (mL\/MIN)<\/h4>\n<p>31\u201350 1\u20132 g every 12 hours16\u201330 1\u20132 g every 24 hours6\u201315 500 mg \u2013 1 g every 24 hours&lt;5 500 mg \u2013 1 g every 48 hours<\/p>\n<h3> DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n<li> CAPD  &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;:Dialysed. 500 mg \u2013 1 g every 24 hours<\/li>\n<li> HD &nbsp;  &nbsp; &nbsp;  &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; :Dialysed. 500 mg \u2013 1 g every 24\u201348 hours<\/li>\n<li>HDF\/high flux  &nbsp; :Dialysed. 500 mg \u2013 1 g every 24\u201348 hours<\/li>\n<li>CAV\/VVHD  &nbsp; &nbsp; &nbsp;:Dialysed. 2 g every 8 hours1 or 1\u20132 g every 12 hours1,2,3CVVhd\/HDFDialysed. 2 g every 12 hours3<br \/>\n<h3> IMPORTANT DRUG INTERACTIONS<\/h3>\n<p>Potentially hazardous interactions with other drugs<\/li>\n<li>Anticoagulants: effects of coumarins may  be enhanced<\/li>\n<li>Ciclosporin: may cause increased  ciclosporin levels<br \/>\n<h3> ADMINISTRATION<\/h3>\n<h4> Reconstition<\/h4>\n<\/li>\n<li>Amount of water for injection to be added  to vials:<\/li>\n<li>1.5 mL to 500 mg vial for IM   administration<\/li>\n<li>5 mL to 500 mg vial for IV injection<\/li>\n<li>3 mL to 1 g vial for IM administration<\/li>\n<li>10 mL to 1 g vial for IV injection \u2014<br \/>\n<h4>  Route<\/h4>\n<p>IV\/IM rarely<\/p>\n<h4>  Rate of Administration<\/h4>\n<p>Bolus: 3\u20134 minutes  Infusion: over 30 minutes<\/p>\n<h4>Comments<\/h4>\n<p>May be given IP in fluid   50\u2013125 mg\/L fluid<\/li>\n<li>Reconstituted solutions vary in colour, but  this is quite normal<\/li>\n<li>Compatible with most IV fluids, e.g.  sodium chloride 0.9%, glucose-saline, glucose 5%<br \/>\n<h4>  OTHER INFORMATION<\/h4>\n<\/li>\n<li>Volume of distribution increases with  infection<\/li>\n<li>In exceptional circumstances, patients on  haemodialysis may be given a dose of 2 g, 3 times a week post HD<\/li>\n","protected":false},"excerpt":{"rendered":"<p>Ceftazidime CLINICAL USE Antibacterial agent DOSE IN NORMAL RENAL FUNCTION<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-1712","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=1712"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1712\/revisions"}],"predecessor-version":[{"id":2829,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1712\/revisions\/2829"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=1712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=1712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=1712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}